Non Small Cell Lung Cancer (Stage III)
16
1
5
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
6.3%
1 terminated out of 16 trials
80.0%
-6.5% vs benchmark
13%
2 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (16)
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment
Response and Toxicity Prediction by Microbiome Analysis After (Concurrent) Chemoradiotherapy
The IVO-LUNG Study
The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective, Single-Arm, Phase II Study
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Patients With Initially Unresectable Stage III NSCLC
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study
Accelerated Radio-Immunotherapy for Lung Cancer
Her2-positive Lung Cancer Treated With Dedicated Drug
High Intensity Functional Image Guided Vmat Lung Evasion
Tumor Mutational Burden in Lung Cancer Patients
A Real-world Study of Durvalumab for Lung Cancer in China
Efficacy and Safety of CRT, Durvalumab and Surgery for SST
Prognostic Evaluation of Tumor Volume and Its Changes in Radical Radiotherapy of Advanced NSCLC
An International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income Countries